The trial of Trillium’s TTI-621 in relapsed or refractory hematologic malignancies is currently in the phase 1a escalation phase and data will be reported in December at ASH 2016. Once MTD has been established the trial will transition to the cohort expansion phase. Data from the heme cohort expansion phase 1b will be provided in 2H/2017. In addition to the five sites involved in the phase 1a, the company envisions adding at least 5-7 additional sites, but have yet to decide where.
Separately, Trillium announced last month that the FDA has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI- 621, in solid tumors and mycosis fungoides. The company anticipates providing an update on that trial in 2H/2017.
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM